OTC · Healthcare
Inotiv, Inc. (NOTVQ)
As-reported financials and recent SEC filings for Inotiv, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$513.0M
Net income
$-68.6M
Net margin
-13.4%
Diluted EPS
$-2.11
ROE
-50.4%
P/E (TTM)
—
Market cap
$348,881
Debt / equity
0.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $513.0M | $490.7M | $572.4M | $547.7M | $89.6M |
| Gross profit | — | — | — | — | $30.2M |
| Operating income | $-30.9M | $-86.4M | $-81.5M | $-263.5M | $-5.6M |
| Net income | $-68.6M | $-108.4M | $-105.1M | $-337.0M | $10.9M |
| Diluted EPS | $-2.11 | $-4.19 | $-4.10 | $-13.84 | $0.19 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →8-K2026-06-08
View on EDGAR →8-K2026-06-03
View on EDGAR →Go deeper on NOTVQ
Search Inotiv, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.